Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Símbolo de cotizaciónPULM
Nombre de la empresaPulmatrix Inc
Fecha de salida a bolsaMar 21, 2014
Director ejecutivoLudlum (Peter B)
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 21
Dirección945 Concord Street
CiudadFRAMINGHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01701
Teléfono18883554440
Sitio Webhttps://www.pulmatrix.com/
Símbolo de cotizaciónPULM
Fecha de salida a bolsaMar 21, 2014
Director ejecutivoLudlum (Peter B)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos